TScan Therapeutics (TCRX) Total Non-Current Liabilities (2020 - 2025)

TScan Therapeutics (TCRX) has 6 years of Total Non-Current Liabilities data on file, last reported at $117.9 million in Q3 2025.

• On a quarterly basis, Total Non-Current Liabilities fell 0.73% year-over-year to $117.9 million in Q3 2025; TTM through Sep 2025 was $117.9 million, a 0.73% decrease from a year earlier, with the FY2024 full-year figure at $130.0 million, changed N/A from the prior year.
• Total Non-Current Liabilities for Q3 2025 stood at $117.9 million, down from $121.7 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for TCRX reached as high as $130.0 million in Q4 2024 and fell as low as $20.7 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $82.3 million across 5 years, with a median of $99.6 million in 2022.
• Across the five-year window, Total Non-Current Liabilities slumped 31.99% in 2022 and soared 511.11% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $27.2 million in 2021, then soared by 265.78% to $99.6 million in 2022, then grew by 22.89% to $122.4 million in 2023, then climbed by 6.21% to $130.0 million in 2024, then decreased by 9.3% to $117.9 million in 2025.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $117.9 million in Q3 2025, $121.7 million in Q2 2025, and $122.4 million in Q1 2025.